As cash runs tight, bluebird plunges after pricing sickle cell gene therapy well above competitor and failing to win review voucher

In­vestors re­act­ed neg­a­tive­ly to blue­bird bio’s pric­ing plans for its new sick­le cell ther­a­py, as well as the lack of a valu­able pri­or­i­ty re­view vouch­er and black box warn­ing for the treat­ment.

Fri­day’s FDA ap­proval of blue­bird’s Lyf­ge­nia came two weeks ahead of sched­ule and on the same day Ver­tex Phar­ma­ceu­ti­cals and CRISPR Ther­a­peu­tics land­ed a his­toric clear­ance for Cas­gevy, their CRISPR-based med­i­cine for the same dis­ease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.